Prophylactic and therapeutic effects of aspirin in cancer.

Authors

Lizet Díaz Peralta, Erika Itayetzi Hernández Torres, Ana Isabel Burguete García, Fernando Luis Reyna Flores, Victor Hugo Bermúdez Morales

Published in

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. Sep 16, 2026. Epub Sep 16, 2026.

Abstract

Aspirin (acetylsalicylic acid) is the oldest synthetic drug and is recognized for its analgesic, antipyretic, antiplatelet effects, and mediators in inflammation. The available research evidence shows that aspirin prevents precursor lesions and cancers, and has therapeutic properties against certain cancer types. This review explores the pharmacological properties of low-dose aspirin related to its preventive effects on cancer, emphasizing the possible mechanisms of action involved in cancer control. It discusses the modulation of signaling pathways related to inflammation, regulation of the cell cycle and apoptosis, inhibition of angiogenesis associated with tumor growth, inhibition of metastasis, and regulation of the immune response. Furthermore, aspirin could be a very promising drug for adjuvant treatment in cancer patients and with implications in the prevention of certain types of cancer.

PMID:
42747715
Bibliographic data and abstract were imported from PubMed on 17 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.